Clinical trials: Breakthrough Cancer Pain
Pain, Cancer
OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
The purpose of this study is to evaluate the long-term safety and efficacy of OraVescent fentanyl to treat breakthrough pain episodes in cancer patients who are already opioid tolerant.
- Trial name
- NCT00105937
- Testing
- OraVescent fentanyl citrate
- Where
- 43 sites in United States
- Volunteers
- 300 people
- Sponsor
- Cephalon
Breakthrough Cancer Pain
Treatment of Breakthrough Cancer Pain According to European Guidelines
Pain is a frequent symptom in cancer patients with a negative impact on the quality of life (QoL).Breakthrough cancer pain (BTcP) is defined as "a transient exacerbation of pain, manifesting spontaneously or related to a specific…
- Trial name
- BEG (NCT04468490)
- Where
- Poland
- Volunteers
- 131 people
- Sponsor
- Aziende Chimiche Riunite Angelini Francesco S.p.A
Breakthrough Cancer Pain
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase I/IIa, pharmacokinetic, dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough…
- Trial name
- NCT04713189
- Testing
- Inhaled fentanyl aerosol
- Volunteers
- 96 people
- Sponsor
- Lee's Pharmaceutical Limited
Cancer, Pain
Effentora® in Clinical Practice - a Non-interventional Study to Evaluate Satisfaction and Tolerability
Aim of this non-interventional study is to investigate the tolerability of Effentora® in cancer pain patients with breakthrough pain under real-life conditions in clinical practice.
- Trial name
- ERKENTNIS (NCT01400854)
- Testing
- Effentora®
- Where
- Germany
- Volunteers
- 600 people
- Sponsor
- Cephalon
Cancers, Pain
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Cancer patients taking regular medication for their pain often still have episodes of severe pain that 'break through' despite their background pain treatment.
- Trial name
- NCT00458510
- Testing
- Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)
- Volunteers
- 403 people
- Sponsor
- Archimedes Development Ltd
Pain
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Primary: To compare the efficacy of nasal fentanyl (NF) to oral transmucosal fentanyl (Actiq®) (hereafter Actiq) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00496392
- Testing
- Nasal fentanyl
- Where
- Denmark
- Volunteers
- 115 people
- Sponsor
- Nycomed
Cancer Pain, Breakthrough Pain
Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. Fentanyl Buccal Tablet (FBT) is used for the treatment of BTP in adults with cancer who are already receiving maintenance opioid therapy for chronic…
- Trial name
- NCT00842829
- Testing
- Fentanyl Buccal Tablet (FBT)
- Where
- 123 sites in France, Germany and 5 more
- Volunteers
- 330 people
- Sponsor
- Cephalon
Cancer
Efficacy and Safety of Intranasal Fentanyl in the Treatment of Breakthrough Pain (FT-018-IM)
Primary objectives: To confirm the efficacy of intranasal fentanyl titrated to doses 50, 100 or 200 µg for treatment of breakthrough pain (BTP) in cancer patients To establish long-term safety of treatment with intranasal…
- Trial name
- NCT00362583
- Testing
- Fentanyl
- Where
- Denmark
- Volunteers
- 100 people
- Sponsor
- Nycomed
Pain, Cancer
A Phase III Clinical Study of KW-2246 for Breakthrough Pain in Cancer Patients
This study is designed to determine whether KW-2246 is superior to placebo and not inferior to immediate-release morphine for the relief of breakthrough pain in cancer patients.
- Trial name
- NCT00684632
- Testing
- KW-2246 (fentanyl citrate)
- Where
- 20 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Respiratory Depression
Long-term Extension Study of BEMA™ Fentanyl
This study is designed to provide continued access to BEMA Fentanyl for those subjects who previously participated in FEN-202 and who wish to continue using BEMA Fentanyl for the treatment of their breakthrough cancer pain.
- Trial name
- NCT00696137
- Testing
- BEMA Fentanyl
- Volunteers
- 5 people
- Sponsor
- BioDelivery Sciences International
Breakthrough Pain
Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent
In the context of radiotherapy, control of breakthrough pain represents a special challenge. Patients undergoing radiotherapy may experience different situations of pain that may be due to the need to remain immobilized during…
- Trial name
- CAVIDIOR (NCT02836379)
- Testing
- No intervention
- Where
- 11 sites in Spain
- Volunteers
- 79 people
- Sponsor
- Angelini Farmacéutica
Breakthrough Cancer Pain
Patient Satisfaction and Quality of Life Impact - PecFent®
National multicenter, prospective, observational study in cancer patients with chronic background pain and breakthrough pain to whom PecFent® has been prescribed under pragmatic condition by a specialist in the treatment of…
- Trial name
- Qualipec (NCT01698645)
- Testing
- PecFent® (fentanyl) nasal spray
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Archimedes Development Ltd
Break Through Pain, Cancer
A Clinical Trial With Intranasal Fentanyl in Cancer Patients With Breakthrough Pain
The aim of this clinical trial was to demonstrate the efficacy of a 400 μg dose strength of intranasal fentanyl spray (INFS, Instanyl®) and to evaluate the safety and to establish long term tolerability of treatment with INFS…
- Trial name
- NOSE-400 (NCT01429051)
- Testing
- Intranasal Fentanyl Spray (INFS)
- Where
- 11 sites in Hungary, Norway and 1 more
- Volunteers
- 46 people
- Sponsor
- Takeda
Pain, Cancer
A Phase III Clinical Study of KW-2246
This study is designed to assess the safety and efficacy of long-term KW-2246 treatment as rescue medication for breakthrough pain.
- Trial name
- NCT00683995
- Testing
- KW-2246 (fentanyl citrate)
- Where
- 20 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Breakthrough Pain
Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain
The primary objective of the study is to determine whether a test titration regimen of ACTIQ treatment will reduce the number of inadequately managed episodes of breakthrough pain for an individual patient by attaining a…
- Trial name
- NCT00236145
- Testing
- ACTIQ (Oral transmucosal fentanyl citrate)
- Sponsor
- Cephalon
Pain, Cancer
Study of BEMA™ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
The purpose of this study is to evaluate the efficacy of BEMA Fentanyl (Onsolis) at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy.
- Trial name
- NCT00293033
- Testing
- BEMA™
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- BioDelivery Sciences International
Pain, Breakthrough Cancer Pain
A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain
The primary objective of this study is to evaluate the efficacy of SSR411298 200 mg daily compared to placebo as adjunctive treatment for persistent cancer pain based on Numeric Rating Scale (NRS).
- Trial name
- ACT11705 (NCT01439919)
- Testing
- SSR411298
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Sanofi
Breakthrough Cancer Pain
Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
The purpose of this observational study is: To observe the efficacy, safety, and tolerability of Abstral ODT for the alleviation of breakthrough cancer pain in Korean patients with various cancers in real-world clinical settings…
- Trial name
- OASIS (NCT03895762)
- Testing
- Abstral Oral Disintegrating Tablet (ODT)
- Where
- South Korea
- Volunteers
- 143 people
- Sponsor
- A.Menarini Asia-Pacific Holdings Pte Ltd
Breakthrough Cancer Pain
Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
The purpose of this study is to determine the prevalence of breakthrough cancer pain and characterize breakthrough cancer pain in an unselected, representative cohort of cancer outpatients with or without pain who attend…
- Trial name
- NCT02899884
- Testing
- No Intervention
- Where
- 36 sites in Spain
- Volunteers
- 3,765 people
- Sponsor
- Takeda
Pain, Cancer
Study of the Safety of BEMA™ Fentanyl Use for Breakthrough Pain in Cancer Subjects on Chronic Opioid Therapy
The purpose of this study is to evaluate the safety of BEMA fentanyl at any dose in the management of breakthrough pain in cancer subjects on background opioid therapy.
- Trial name
- NCT00293020
- Testing
- BEMA Fentanyl
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- BioDelivery Sciences International